Craniofacial osteo‑ and chondro‑sarcomas remain a therapeutic challenge: high local relapse rate, limited systemic options and scarce pre‑clinical models. Two‑dimensional cell lines fail to mimic extracellular matrix, while in‑vivo xenografts are costly and slow.
TRZYDE builds a rapid 3‑D bioprinted platform that replicates the tumour micro‑environment within days, enabling high‑throughput compound screening and mechanistic insight into the MDM2‑p53 axis.
The project is being shaped for the upcoming NCBR "Ścieżka SMART – FENG 2021‑2027" call (Q3 2025). This EU‑backed programme funds industrial research and experimental development for Polish SMEs up to 80% of project value.
Potent oral MDM2–p53 antagonist
Next‑gen MDM2 inhibitor (phase III)
Benchmark first‑generation MDM2 ligand
Import test batch (BI‑907828), customs, HPLC‑MS validation.
Establish GelMA scaffolds, live‑dead QC, baseline transcriptomics.
Brigimadlin dose‑response, Milademetan head‑to‑head, Nutlin‑3a calibration.
Full proposal to NCBR with preliminary IC50 data & imaging pipeline.
TRL‑6 prototype ready for CRO contract screening and pharma partnerships.
Warsaw Tech
National Oncology Institute
Radfarm Analytics